Unknown

Dataset Information

0

Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.


ABSTRACT: Regulatory T (Treg) cells play a central role in immune tolerance and prevention of aberrant immune responses. Several studies have suggested that the risk of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) can be ameliorated by increasing Tregs. We have developed an approach of in vivo expansion of Tregs with RGI-2001, a novel liposomal formulation of a synthetic derivative of alpha-galactosylceramide, a naturally occurring ligand that binds to CD1 and activates and expands invariant natural killer cells. In preclinical studies, a single intravenous infusion of RGI-2001 expanded Treg and could ameliorate GVHD in a mouse model of allogeneic HCT. To explore the role of RGI-2001 in clinical HCT, we initiated a phase 2A clinical trial (n?=?29), testing 2 different doses of RGI-2001 administered as a single infusion on day 0 of allogeneic HCT. RGI-2001 was well tolerated and without infusion reactions or cytokine release syndrome. A subset of patients (8 of 29, 28%) responded to RGI-2001 by inducing a markedly increased number of cells with a Treg phenotype. The Treg had a high Ki-67 index and were almost exclusively Helios+ and Foxp3+, indicating that their accumulation was due to expansion of natural Treg. Notably, the incidence of grade 2 to 4 GVHD in the 8 patients who responded to RGI-2001 was 12.5%, compared with 52.4% in the 21 patients who did not respond. No grade 3 or 4 GVHD was observed in the responder group, compared with a 9.5% incidence among nonresponders. Immunosuppression with sirolimus was also associated with a low incidence of GVHD, suggesting that RGI-2001 may have synergized with sirolimus to promote Treg expansion.

SUBMITTER: Chen YB 

PROVIDER: S-EPMC5437739 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Increased Foxp3<sup>+</sup>Helios<sup>+</sup> Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Chen Yi-Bin YB   Efebera Yvonne A YA   Johnston Laura L   Ball Edward D ED   Avigan David D   Lekakis Lazaros J LJ   Bachier Carlos R CR   Martin Paul P   Duramad Omar O   Ishii Yasuyuki Y   Han Semi S   Jung Yu-Jin YJ   Lee Dana D   Kunkel Lori L   Negrin Robert S RS   Bui Jack D JD  

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20170116 4


Regulatory T (Treg) cells play a central role in immune tolerance and prevention of aberrant immune responses. Several studies have suggested that the risk of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) can be ameliorated by increasing Tregs. We have developed an approach of in vivo expansion of Tregs with RGI-2001, a novel liposomal formulation of a synthetic derivative of alpha-galactosylceramide, a naturally occurring ligand that binds to CD1 and  ...[more]

Similar Datasets

| S-EPMC8139402 | biostudies-literature
| S-EPMC6615958 | biostudies-literature
| S-EPMC5445103 | biostudies-literature
| S-EPMC6943339 | biostudies-literature
| S-EPMC8563377 | biostudies-literature
| S-EPMC5534641 | biostudies-other
| S-EPMC6548580 | biostudies-literature
| S-EPMC3327459 | biostudies-literature
| S-EPMC4980213 | biostudies-literature
| S-EPMC6138764 | biostudies-literature